Dystonia-deafness syndrome caused by a β-actin gene mutation and response to deep brain stimulation

Mov Disord. 2017 Jan;32(1):162-165. doi: 10.1002/mds.26842. Epub 2016 Nov 8.

Abstract

Introduction: Dystonia-deafness syndrome is a distinct clinical presentation within the dystonia-spectrum. Although several genetic and acquired causes have been reported, etiology remains unknown in the majority of patients.

Objectives: To describe two patients with dystonia-deafness syndrome due to a beta-actin gene mutation.

Methods: We report on disease course, genetic testing, and management of 2 patients, mother and daughter, presenting with dystonia-deafness syndrome.

Results: After exclusion of known dystonia-deafness syndrome causes, whole-exome sequencing revealed a beta-actin gene mutation (p.Arg183Trp) in both patients. Although beta-actin gene mutations are generally associated with developmental Baraitser-Winter syndrome, dystonia-deafness syndrome has been reported once in identical twin brothers. Bilateral GPi-DBS led to a significant decrease of dystonia and regain of independency in our patients.

Conclusion: The p.Arg183Trp mutation in the beta-actin gene is associated with the clinical presentation of dystonia-deafness syndrome, even with only minimal or no developmental abnormalities of Baraitser-Winter syndrome. GPi-DBS should be considered to ameliorate the invalidating dystonia in these patients. © 2016 International Parkinson and Movement Disorder Society.

Keywords: Baraitser-Winter syndrome; beta-actin; deep brain stimulation; dystonia; dystonia-deafness syndrome.

Publication types

  • Case Reports

MeSH terms

  • Actins / genetics*
  • Adult
  • Deaf-Blind Disorders / genetics*
  • Deaf-Blind Disorders / therapy*
  • Deep Brain Stimulation / methods*
  • Dystonia / genetics*
  • Dystonia / therapy*
  • Female
  • Humans
  • Intellectual Disability / genetics*
  • Intellectual Disability / therapy*
  • Middle Aged
  • Mothers
  • Mutation
  • Nuclear Family
  • Optic Atrophy / genetics*
  • Optic Atrophy / therapy*
  • Young Adult

Substances

  • Actins

Supplementary concepts

  • Mohr-Tranebjaerg syndrome